A detailed history of Qube Research & Technologies LTD transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 273,158 shares of PBYI stock, worth $699,284. This represents 0.0% of its overall portfolio holdings.

Number of Shares
273,158
Previous 387,178 29.45%
Holding current value
$699,284
Previous $2.05 Million 56.63%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.92 - $5.83 $332,938 - $664,736
-114,020 Reduced 29.45%
273,158 $890,000
Q1 2024

May 14, 2024

BUY
$4.29 - $7.4 $1.13 Million - $1.95 Million
264,018 Added 214.37%
387,178 $2.05 Million
Q4 2023

Feb 13, 2024

BUY
$2.23 - $4.49 $256,026 - $515,496
114,810 Added 1374.97%
123,160 $533,000
Q3 2023

Nov 13, 2023

BUY
$2.63 - $4.09 $21,960 - $34,151
8,350 New
8,350 $21,000
Q1 2023

May 15, 2023

BUY
$2.21 - $4.82 $44,325 - $96,674
20,057 Added 35.42%
76,685 $236,000
Q4 2022

Feb 14, 2023

BUY
$2.12 - $5.08 $63,775 - $152,821
30,083 Added 113.33%
56,628 $239,000
Q3 2022

Nov 14, 2022

SELL
$2.27 - $3.84 $6,276 - $10,617
-2,765 Reduced 9.43%
26,545 $63,000
Q2 2022

Aug 15, 2022

BUY
$1.64 - $3.3 $48,068 - $96,723
29,310 New
29,310 $84,000
Q3 2021

Nov 12, 2021

SELL
$6.63 - $9.39 $303,501 - $429,846
-45,777 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$8.98 - $11.6 $411,077 - $531,013
45,777 New
45,777 $420,000
Q3 2020

Nov 12, 2020

SELL
$9.5 - $11.14 $225,625 - $264,575
-23,750 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$7.01 - $13.24 $166,487 - $314,450
23,750 New
23,750 $248,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $117M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.